Mode
Text Size
Log in / Sign up
N/A N=50 Randomized Treatment

BPD Saturation TARgeting

Bronchopulmonary Dysplasia · Chronic Lung Disease of Prematurity · Chronic Lung Disease

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcome: Primary: Intermittent Hypoxemia (IH) Events Per 8 Hours of Monitoring Time — 2.2; 1.2 IH events per 8 hours of monitoring time

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
LOWER oxygen saturation target group (Other); HIGHER oxygen saturation target group (Other)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Children's Hospital of Philadelphia
Primary completion
Feb 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Intermittent Hypoxemia (IH) Events Per 8 Hours of Monitoring Time
2.2; 1.2
SECONDARY
Duration of Hypoxia - Proportion of Monitored Time With Oxygen Saturation <80%
0.005; 0.004
SECONDARY
Change in Weight Z-score
0.6; 0.5
SECONDARY
Change in Length Z-score
1.7; 1.2
SECONDARY
Change in Head Circumference Z-score
0.5; 0.4
SECONDARY
Number of Participants With Re-hospitalization
9; 6
SECONDARY
Number of Participants With Respiratory Medication Use
6; 6
SECONDARY
Number of Participants With Visits to Emergency Room or Urgent Care for Respiratory Reasons
5; 2
SECONDARY
Feeding
1; 0
SECONDARY
Development
8; 3

Summary

Bronchopulmonary dysplasia (BPD), or chronic lung disease of prematurity, affects nearly half of extremely preterm infants.This study evaluates the use of supplemental oxygen to manage infants with established BPD. Participants will be randomly placed in either a higher oxygen saturation group or a lower oxygen saturation target group.

Eligibility Criteria

Inclusion Criteria

  • Pre-term males or females infants born at <30 0/7 weeks gestation at birth
  • Current age 34 0/7 to 43 6/7 weeks postmenstrual age
  • Diagnosis of moderate or severe Bronchopulmonary Dysplasia based on the NIH consensus definition
  • Infant has never been discharged to home from the hospital

Exclusion Criteria

  • Congenital anomaly or oncologic process likely to affect growth or respiratory status
  • Hemoglobinopathy or other blood disorder likely to affect oxygen saturations
  • Contraindication to nasal cannula use (for example, severe nasal septal breakdown).
  • Pulmonary hypertension requiring pharmacotherapy at the time of screening/enrollment.
  • Tracheostomy
  • Intubated during entire eligibility period
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03385330). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search